Center for Cancer Immunology and Immunotherapy (CCII)

这项计划的目标是建立一个主题多学科的卓越研究中心 路易斯维尔大学(UofL)命名为癌症免疫和免疫治疗中心(CCII)。这个 CCII的使命是进行杰出的生物医学研究，致力于利用 免疫系统来根除癌症。目前人们对……的前景非常乐观。 鉴于最近免疫检查点抑制剂、溶瘤病毒、 以及采用细胞移植疗法。免疫疗法有可能用于治疗所有类型的癌症。 并诱导持久的缓解或治愈。然而，还需要更多的研究和开发来 充分发挥癌症免疫治疗的潜力。路易斯维尔大学非常有资格成为 CCII的总部所在地有很多原因，包括我们10年来进行临床试验的记录 免疫治疗药物，独特的资源，包括从这些试验中获得人类样本，我们的 高级研究人员在癌症免疫学方面的专业知识，我们对翻译研究的关注，以及 这只科布雷将处于全国癌症死亡率最高的州。重要的是，这所大学 在使这个拟建的中心取得成功方面投入了大量资金，最好的证明是 在五年内提供1680万美元的机构承诺。CCII计划的两个PI受到高度重视 该领域的专家，他们做出了开创性的贡献，从基础癌症免疫学到关键 癌症免疫疗法的临床试验。具有主题领域专业知识的高级导师和强大的 资助、出版物、指导和研究部门服务的历史将支持CCII的指导使命， 拥有基本专业知识(行政、生物统计学和生物信息学)的联合调查组也将如此。 以及内部和外部咨询委员会。功能免疫组学核心将提供重要的新 基础设施和利用现有资源(包括其他创意计划)以提供出色的支持 感谢被选为CCII项目第一批绩效指标的四名有前途的初级调查人员。这个 CCII的四个总体具体目标是：(1)为 CCII；(2)创建一个研究核心，在利用现有设施的同时提供新的能力；(3)支持 专题领域初级专业人员的研究和职业发展；以及(4)制定和启动一项 CCII的长期可持续性和增长。我们有信心这个新的科布雷中心将导致 在头五年为4-6名CCII初级调查人员颁发创新的R01补助金，其中许多 毕业生将继续是这个新中心的关键成员，以进一步建设未来的中心。多数 重要的是，我们将严谨的基础科学与高度可翻译的动物和人类标本相结合 研究最终应该有助于开发新的治疗策略，这将有助于改善 全球每年被诊断为癌症的1700多万人的前景。

The objective of this program is to establish a thematic multidisciplinary research center of excellence at the University of Louisville (UofL) named the Center for Cancer Immunology and Immunotherapy (CCII). The mission of the CCII is to conduct outstanding biomedical research that works towards harnessing the power of the immune system to eradicate cancer. There is currently a great deal of optimism about the prospects for cancer immunotherapies given the recent clinical successes of immune checkpoint inhibitors, oncolytic viruses, and adoptive cell transfer therapies. Immunotherapies have the potential to be used to treat all types of cancer and to induce long-lasting remissions or cures. However, more research and development is needed for cancer immunotherapy to reach its full potential. The University of Louisville is exceptionally qualified to be the home of the CCII for many reasons including our 10-year track record of conducting clinical trials of immunotherapeutic agents, unique resources that include access to human specimens from these trials, our senior investigators’ expertise in cancer immunology, our focus on translational research, and the impact that this COBRE would have in a state with the highest cancer death rates in the nation. Importantly, the University of Louisville is highly invested in making this proposed center a success as best evidenced by more than $16.8M in institutional commitments over five years. The two PIs of the CCII program are highly regarded experts in the field who have made seminal contributions spanning from basic cancer immunology to pivotal clinical trials of cancer immunotherapies. Senior mentors with expertise in the thematic area and a strong history of funding, publications, mentoring, and study section service will support the CCII’s mentoring mission, as will a team of co-investigators with essential expertise (in administration, biostatistics, and bioinformatics) and Internal and External Advisory Committees. A Functional Immunomics Core will provide important new infrastructure and leverage existing resources (including other IDeA programs) to provide outstanding support to the four promising junior investigators who have been selected as the first cohort of CCII Project PIs. The four overall specific aims of the CCII are to: (1) Establish the administrative and mentoring infrastructure for the CCII; (2) Create a research core that provides new capabilities while leveraging existing facilities; (3) Support the research and career development of junior PIs in the thematic area; and (4) Develop and initiate a plan for long-term sustainability and growth of the CCII. We are confident that this new COBRE center will lead to the awarding of innovative R01 grants for 4-6 CCII junior investigators in the first five years and that many of these graduates will remain key members of this new COBRE to further build the center in the future. Most importantly, our combination of rigorous basic science with highly translational animal and human specimen studies should ultimately contribute to the development of new treatment strategies that will help to improve the outlook for the more than 17 million people worldwide who are diagnosed with cancer each year.